SGMT vs UTHR · $403.2M cap vs P/E 20, rev $1.56B
Sagimet Biosciences Inc. Series A Common Stock (SGMT) versus United Therapeutics Corporation (UTHR) — a side-by-side from cached financials, not a winner call.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
SGMT does not have a complete income-statement cache yet.
Latest reported UTHR revenue for 2026-06-30 was $1.56B. Net income was $607.9M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
SGMT currently screens at market cap $403.2M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Not investment advice. Open the SGMT and UTHR stock pages for the full models.
Not investment advice.